Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
ID: 345845Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345845

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-037.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data." This initiative aims to support innovative analyses of existing datasets to investigate substance use behaviors, including alcohol, tobacco, and HIV prevention, without the need for primary data collection. The program is particularly significant as it seeks to leverage previously collected data to enhance understanding of drug use etiology and epidemiology, ultimately guiding effective prevention and treatment strategies. Interested applicants can apply for funding up to $275,000 over a two-year period, with a total funding availability of $2 million for fiscal years 2023-2025. The application deadline is November 15, 2024, and further inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-24-037-Full-Announcement.html
    RFA-DA-24-037.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), invites applications for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data." This initiative focuses on innovative analysis of existing datasets to study substance use behaviors and related disorders, including alcohol, tobacco, and HIV prevention. Applicants are encouraged to utilize various public datasets without any primary data collection. The funding availability is $2 million for fiscal years 2023-2025, with project budgets not exceeding $275,000 over two years. Key deadlines for submissions include multiple due dates with the earliest starting on March 7, 2023, and a final expiration of November 16, 2024. Projects aimed at advancing understanding of substance use through various methodologies, including big data analytics and multi-source data integration, are particularly encouraged. The target applicants include diverse organizations, including higher education institutions and nonprofits, and all applications require adherence to strict NIH guidelines and submission processes outlined in the FOA. This funding aims to leverage extensive, previously collected data to address critical substance use issues effectively.
    Similar Opportunities
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at accelerating substance use research through the utilization of existing data, specifically under the R21 grant mechanism. This initiative seeks to foster innovative research projects that leverage pre-existing datasets to enhance understanding and treatment of substance use disorders. The total estimated funding for this program is $2 million, with an award ceiling of $200,000 per project and an anticipated three awards to be made. Interested applicants should note that the NOFO is expected to be published in Fall 2024, with applications due in Spring 2025, and the estimated award date is set for April 1, 2026.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for research aimed at accelerating the pace of substance use research using existing data, specifically under the R01 grant mechanism. This initiative seeks to promote innovative research projects that leverage existing datasets to enhance understanding and treatment of substance use disorders, with the goal of fostering meaningful collaborations among researchers. The estimated total program funding is $2 million, with approximately three awards expected to be made, and the anticipated application due date is in Spring 2025, following the publication of the Notice of Funding Opportunity in Fall 2024. For further details, potential applicants should prepare to submit their proposals by the estimated close date of June 17, 2025, with awards expected to be announced by April 1, 2026.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.